Analysing the next-generation Biologics market 2016-2026

What is the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis.  A new study by Visiongain of London, UK, reveals what is possible for biological drugs – their lucrative next phase, developments in that industry and market, discovering expected progress and revenues.

New biotechnological medicines will benefit patients and pharmaceutical companies.

The updated report gives sales forecasts to 2026 at overall world, submarket, product and national level. Industry-watchers see what the future holds, assessing gains for developers and producers.

Many opportunities exist. And besides giving revenue predictions, the analysis shows you recent results, growth rates and market shares. In that report you discover 127 tables, 47 charts and four interviews with companies. Covered in the report are prospects for that world market and submarkets possible for next-generation biopharmaceutical and  overall world sales to 2026 for those emerging biotherapies

Also there are individual revenue predictions to 2026 for six next-generation biologic submarkets at world level and their further subdivisions:
• Next-generation antibody therapies, including the subsectors of antibody-drug conjugates (ADCs), engineered antibodies and bispecific treatments
• Next-generation antibody fragments and antibody-like proteins (ALPs)
• Next-generation insulins, including submarkets assessing oral insulins, ultra-long and ultra-rapid acting therapies
• Next-generation recombinant coagulation factors
• Next-generation growth hormones
• Regenerative medicine, including tissue engineering, gene therapies and stem cells.

The report predicts revenues of eight top brands:
• Kadcyla
• Adcetris
• Tresiba
• Alprolix
• Eloctate
• Gazyva/Gazyvaro
• Plegridy
• Afrezza.

Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Many opportunities exist for new, improved treatments. Nine national markets are covered:
United States
Japan
Germany, France, United Kingdom, Italy and Spain
China
India.

 

The report explains trends, processes and events affecting the follow-on biopharmaceuticals industry and market from 2016, including these forces:
• Demands and needs for new biological therapies
• Limitations of existing medicines
• Promise of next-generation biologics and product launches
• Extension of half-life – pegylation and other technologies
• Contract manufacturers (CMOs) serving those developmental needs and trends.

And you explore these influences, among others:
• Disease incidence and prevalence affecting demand for those new medicines
• Improvements in therapeutic antibodies and variants, including targeted cytotoxic therapies
• R&D pipelines – e.g. for immunotoxins – including agents in clinical development
• Biosimilars and other follow-on protein agents transforming the biologics market
• Effects of rising incidence rates in diabetes, cardiovascular disorders and cancer.

The report predicts the next-generation biologics market will reach $21.3bn worldwide in 2020, with strong revenue growth to 2026. See what the future holds for those products. To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com – PRNewswire.

Related Posts

Leave a Reply